PeptideStack
5.2kquestions
20kanswers
220users

What does 96.8% purity on a C4 column actually tell me about a dulaglutide vial?

Asked 2 Jun 2024Modified 23 months agoViewed 51k times
31

Concretely: 96.8% · a C4 column · dulaglutide.

I would like to know the limits of what can be inferred from this.

What I am trying to avoid is over-reading a single result, which I have done before.

What can I legitimately conclude from this figure?

hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

466 questions
purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

749 questions
shareeditfollowflag
MV
askedmala_venkatesh21k282 Jun 2024

5 Answers

Accepted answer first, then by votes
81

Accepted answer

Method transfer between laboratories is almost impossible without full documentation, which is why two labs reporting the same preparation should expect disagreement.

Reverse-phase stationary phases use C18 or C8 chains bonded to silica, and the pore size of the silica matters more for a peptide of this chain length than the ligand length does.

Trifluoroacetic acid at 0.1 per cent is the standard ion-pairing agent because it suppresses tailing by neutralising the basic residues, but it also suppresses mass spectrometry signal.

Inter-laboratory studies using identical methods on identical material show precision well within half a per cent when the method is locked down, pointing to method variability as the primary source of disagreement.

Ask for the chromatogram and the system suitability data, not just the number.

shareimprove this answerflag
LT
answered · acceptedlane_transit42k3822 Jul 2024
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
30

The most important parameter is the one that is almost never specified: the gradient slope during the region where your main peak elutes.

Mobile phase pH at the point where you inject must match the mobile phase pH at the start of the gradient, or the sample will not be focused at the column head.

Formic acid is the compromise when you need the mass spectrometer on the same run, but the peak shape penalty is real and easily a tenth of a per cent on purity.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.

shareimprove this answerflag
MO
answeredmarta_okonkwo87k2583 Aug 2024
22

High-performance liquid chromatography is a separation technique, not an identification technique, and it answers the question "how much of the detected signal is a single species" not "which species is it."

Wider-pore phases — 300 Angstrom rather than 100 Angstrom — have faster mass transfer and narrower peaks for peptides above three kilodaltons, which is almost every peptide you will see.

Worth being precise here: temperature affects both the viscosity of the mobile phase and the dynamics of molecular interactions, and a method developed at 25 degrees and run at 40 degrees will not behave identically.

I would caution against over-interpreting small differences between runs, because the noise floor of the method is larger than most people assume.

If two labs give different numbers, the method difference is the first hypothesis, not lab quality.

shareimprove this answerflag
TU
answeredtenth_of_a_unit40k3830 Jun 2024
5I would add a sentence about sterility here, since it is the thing people skip. – tenth_of_a_unit 3 months ago
6The placebo-arm figure is the part everyone omits. – Dr_Hanne_Solberg 5 months ago
add a comment
17

It helps to be literal here: system suitability is the part of a report that tells you whether the method was under control on the day you were tested, and its absence is concerning.

Proline-rich sequences are particularly problematic because the isomerisation kinetics are in the same timescale as the separation, leading to split or broadened peaks at low temperature.

The limitation is that co-elution is invisible — if two species happen to have the same retention time, they will report as a single peak at their combined area.

Ask for the chromatogram and the system suitability data, not just the number.

edited 15 Jul 2024 by Dr_Hanne_Solberg — removed a claim I could not source

shareimprove this answerflag
DS
answeredDr_Hanne_Solberg40k3812 Jul 2024
6Related: the same reasoning applies to the counter-ion question. – Dr_Yusuf_Adeyemi 7 months ago
add a comment
14

To be exact about it, the chemistry of peptides at low pH and high organic-solvent concentration is not something most users have intuition for, which is why published methods exist.

Sample preparation is almost always under-appreciated — a reconstituted peptide in strong solvent will distort its own peak on the gradient.

Peptide separation by reverse-phase high-performance liquid chromatography is described in the general chapters of the United States Pharmacopeia, European Pharmacopeia and Japanese Pharmacopeia, and the methods converge on essentially the same principles.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.

shareimprove this answerflag
DS
answereddmitri_savchuk17k165 Sept 2024
8I have seen exactly this failure mode twice and both times it was the diluent. – Dr_Jonas_Halvorsen 9 months ago
The distinction between purity and content cannot be repeated often enough here. – e_dziedzic 21 days ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.